Industry & Policy News

[Stanford Medicine] Ravi Majeti and his colleagues programmed mouse leukemia cells so that some of them could be induced to transform themselves into cells that attacked the cancer from which the cells were derived.

[Nexcella, Inc.] Nexcella, Inc. announced 50 relapsed/refractory multiple myeloma patients had already been dosed with next-generation CAR-T NXC-201 in its ongoing Phase Ib/IIa clinical trial. Nexcella anticipated 100-patient open-label total enrollment to seek US FDA BLA approval.

[Asklepios BioPharmaceutical, Inc.] Asklepios BioPharmaceutical, Inc. announced that the European Commission has granted orphan drug designation for AB-1003 for the treatment of limb-girdle muscular dystrophy (LGMD). AB-1003 is a novel investigational recombinant adeno-associated virus based gene therapy currently being developed as a one-time intravenous infusion for the treatment of patients with LGMD type 2I/R9.

[Regeneron Pharmaceuticals, Inc.] Regeneron Pharmaceuticals, Inc. and Sanofi announced that the US FDA has approved Kevzara® for the treatment of polymyalgia rheumatica, an inflammatory rheumatic disease, in adult patients who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper.

[Carleton University] Carleton University researchers have received over $3 million from the Canadian Institutes for Health Research (CIHR). The funding will support projects developing solutions to the prevalence of diabetes, chronic pain, gut health disturbances and brain injuries.

[ScienceInsider] Researchers in the United Kingdom (UK) breathed a cautious sigh of relief yesterday after the government struck a deal with the European Union (EU) to fix post-Brexit disputes over issues including trade across Northern Ireland’s border.